Seattle Genetics Inc. (SGEN) announced Tuesday morning that the FDA has put a clinical hold or partial clinical holds on several early stage trials of vadastuximab talirine in the treatment of acute myeloid leukemia. The FDA took action after six patients were identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events.
from RTT - Before the Bell http://ift.tt/2hw9Zi6
via IFTTT
No comments:
Post a Comment